Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

2 years ago

Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and…

Regeneron Announces Investor Conference Presentations

2 years ago

TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • 2023…

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

2 years ago

BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical…

RxSight, Inc. to Present at the Wells Fargo Healthcare Conference

2 years ago

ALISO VIEJO, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality…

Societal CDMO Announces Appointment of Matt Arens to Board of Directors

2 years ago

Experienced Health Care Industry Investor with Track Record of Identifying Innovative Life Science Companies with High Growth PotentialSAN DIEGO and…

Societal CDMO Announces Proposed Public Offering of Common Stock

2 years ago

SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development…

BioCryst to Present at Upcoming Investor Conferences

2 years ago

RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will…

MDxHealth Reports Q2 and Half Year 2023 Results

2 years ago

NEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET             MDxHealth Reports Q2 and Half Year…

Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting

2 years ago

Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a…

Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression

2 years ago

World-first take-home approvalsThe first doses of MB22001 have been administered in an 8 week treatment protocolVANCOUVER, BC / ACCESSWIRE /…